The Relationship between Adiponectin and Breast Cancer

Erbay, Burcu; Yılmaz, Tonguç Utku; Eraldemır, Ceyla; Üren, Nihal; Tiryaki, Çağrı; Utkan, Zafer

doi:10.5152/tjbh.2016.2881

Cited by 10 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…demonstrated that the presence of the TG genotype at the position +45 of the ADIPOQ gene may be associated with the risk of BC in obese Indian women. By contrast, Khandouzi et al ., Erbay et al . and Teras et al .…”

Section: Discussionmentioning

confidence: 84%

Genetic and epigenetic modifications of adiponectin gene: Potential association with breast cancer risk

Pasha

Mohamed

Toam

et al. 2019

The Journal of Gene Medicine

View full text Add to dashboard Cite

Background: Adipokines produced by adipose tissue are directly linked to obesity and may contribute to the pathogenesis of cancer. We hypothesized that genetic and epigenetic modifications in the adiponectin (ADIPOQ) gene and their impact on serum ADIPOQ levels may participate in increasing breast cancer (BC) risk. The present study aimed to investigate ADIPOQ +45 T/G gene polymorphism, methylation status at CpG sites −74 nucleotides (nt) and −283 nt of the ADIPOQ gene, and ADIPOQ serum levels in BC obese women.Methods: Serum ADIPOQ was measured by an enzyme-linked immunosorbent assay. ADIPOQ +45 T/G gene polymorphism and ADIPOQ promoter methylation status were determined using a polymerase chain reaction (PCR) and a methylationspecific PCR, respectively, in 120 obese women with BC and 120 age-matched controls.Results: ADIPOQ +45 GG genotype carriers had a significant increased risk of developing BC (odds ratio = 6.2, 95% confidence interval = 1.3-29.6, p = 0.02).ADIPOQ gene methylation at site −74 nt resulted in a 1.7-fold increased BC risk.Methylation at site -283 nt resulted in a 1.9-fold increased BC risk. Moreover serum levels of ADIPOQ were significantly decreased in BC patients and down-regulated in the presence of methylation in both examined sites. By contrast, no association between ADIPOQ gene polymorphism and serum ADIPOQ level was detected. Using both methylated sites in one panel detected cancer breast with 76.67% sensitivity and 62.18% accuracy.Conclusions: ADIPOQ +45 T/G polymorphism and ADIPOQ promoter methylation were found to be associated with BC risk in obese Egyptian women.

show abstract

Section: Discussionmentioning

confidence: 84%

Genetic and epigenetic modifications of adiponectin gene: Potential association with breast cancer risk

Pasha

Mohamed

Toam

et al. 2019

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

“…Moreover, obese BC patients are known to have a higher risk of LN metastasis, larger tumors, and higher death rates compared with non-obese patients (Rose and Vona-Davis 2010). These increased risks might be due to elevated estrogen levels that occur from enhanced aromatization in adipose tissue and increases in the levels of mitogenic agents such as insulin and/or IGF associated with obesity-related metabolic syndromes (DM and BC) (Erbay et al 2016). In addition to increased estrogen levels, increases in insulin levels may also contribute to the development of BC by enhancing insulin-like growth factor-I (IGF-1) receptor-mediated release of VEGF from breast tissues (Erbay et al 2016), which could couple with effects associated with increased leptin levels (Belfiore 2007).…”

Section: Discussionmentioning

confidence: 99%

“…These increased risks might be due to elevated estrogen levels that occur from enhanced aromatization in adipose tissue and increases in the levels of mitogenic agents such as insulin and/or IGF associated with obesity-related metabolic syndromes (DM and BC) (Erbay et al 2016). In addition to increased estrogen levels, increases in insulin levels may also contribute to the development of BC by enhancing insulin-like growth factor-I (IGF-1) receptor-mediated release of VEGF from breast tissues (Erbay et al 2016), which could couple with effects associated with increased leptin levels (Belfiore 2007). Moreover, the adverse influence of DM on the prognosis of cancer patients with malignancies is likely associated with effects of insulin on the tyrosine kinase growth receptor pathway (Belfiore 2007).…”

Section: Discussionmentioning

confidence: 99%

Molecular Profiling of Breast Cancer Susceptibility of Obese or Insulin-Resistant and Pre-Diabetic Patients Using ITLN1 and CD295 SNPs

Hamdy

El-Shemy

2020

Preprint

View full text Add to dashboard Cite

Mutations in cluster of differentiation (CD) 295 gene, encoding class I cytokine receptor, are associated with obesity and breast cancer (BC). SNPs in the adipocyte-inferred novel cytokine intelectin 1 (ITLN1) remain understudied in connection to CD295 polymorphisms and diabetes mellitus (DM) or a pre-diabetic state, as well as to DNA damage seen in BC. We will explore whether CD295 (ID rs6700896) and ITLN1 (rs rs952804) SNPs impact BC with or without DM, insulin resistance (IR) or obesity. Effects of ITLN1 or CD295 polymorphism(s) on DNA damage in BC were also examined. Blood samples from 170 women with BC (including 33 and 48 with DM and pre-diabetes, respectively) and from 108 age-matched women in the control group were collected. Plasma insulin, leptin, CD295, and ITLN1 levels were measured by ELISA. DNA damage was assessed using an alkaline comet assay. BC cases with clinical stage T II and positive LN as well as tumor histologic grade III, presence of obesity, pre-diabetic events, DM or IR were associated with CD295 rs6700986 mutant homozygous (CC) and heterozygous (CT) genotype and ITLN1 rs952804 mutant heterozygous genotype (CT) (P ≤ 0.05). Tail DNA (%) and tail moment units were significantly associated with CD295 rs6700986 CT and ITLN1 rs952804 TT genotypes. C allele (CT+CC vs. TT) and T allele (TT+CT vs. CC) for CD295 rs6700986 and ITLN1 rs952804, respectively, were associated with BC risk (P ≤ 0.05). ITLN1 (rs952804) and CD295 (rs6700986) SNPs should be considered as BC associated-susceptibility risk factors in obese, insulin resistant, or pre-diabetics.

show abstract

“…Understanding the underlying molecular features of special types of breast cancer will provide new approaches and new study areas for the treatment modalities. There are several genetic alterations that might help target the treatment (34). With the increase in the understanding of genetic background of the breast cancer in different geographic regions, we can target the new treatment approaches.…”

Section: Discussionmentioning

confidence: 99%

Characteristics of Special Type Breast Tumors in Our Center

Yılmaz

Trabzonlu

Güler

et al. 2018

Eur J Breast Health

Self Cite

View full text Add to dashboard Cite

IntroductionBreast cancer, which is the most diagnosed cancer among women, is a heterogeneous disease, consisting of numerous, distinct clinical and biological features. Breast cancer is a collection of different diseases with different risk factors, clinical presentations, pathological features, and treatment responses and outcomes. In order to classify different breast cancers, several parameters have been used. Tumor grade, Tumor Node Metastasis (TNM) staging, histological classification, existence of axillary lymph node metastasis, immunohistochemical biomarker characterization, and molecular profiling are the parameters used for classification of breast tumors (1).Histological type is derived from the growth pattern of the breast tumors. Specific morphological and cytological patterns are associated with distinctive clinical presentations and/or outcomes (2). The most common type of breast cancer is an invasive ductal carcinoma (IDC). In the last version of the World Health Organization classification, at least 17 distinct histological special types have been recognised and specialized types account for up to 25% of all breast cancers (3). Special or rare breast tumor terminology was first described in the study of Weigelt B. et al. (2). Although new treatment protocols depend on molecular findings, histological groups still carry important clinical implications (3). As the prevalence of special type breast cancer is low, not as many studies are concerned with the clinical and molecular characteristics of special type breast cancer (4). In this study, we aimed to describe the clinical features of special type breast cancer in our center. Eur J Breast Health 2018; 14: 17-22 DOI: 10.5152/ejbh.2017.3219 17 ABSTRACT Objective: Breast cancer is a heterogeneous disease with different histological types. Ductal breast cancer constitutes the vast majority of the breast cancers. However limited data are present in the rest of breast cancers called special or rare type breast cancers. Here in this study, we tried to describe the clinical features of special type breast cancers in our center. Characteristics of Special Type Breast Tumors in Our Center Materials and Methods:Retrospective descriptive study was performed in Kocaeli University School of Medicine, Department of General Surgery between January 2000 and January 2016. Women diagnosed with primary breast cancer other than ductal carcinoma were included to the study. In total, 101 patients were evaluated according to histologic types, molecular types, Tumor Node Metastasis (TNM) stages, and grades. Survival of the patients was also evaluated.Results: Medullary and metaplastic types showed basal type; tubular, mucinous, micropapillary carcinoma, cribriform, lobular and apocrine tumors showed luminal type molecular pattern. Neither the existence of ductal carcinoma nor any histologic types had any effects on survival. Apocrine tumors were presented in younger ages. Conclusion:Histologic types of breast cancer are closely related with the molecular types of t...

show abstract

The Relationship between Adiponectin and Breast Cancer

Cited by 10 publications

References 35 publications

Genetic and epigenetic modifications of adiponectin gene: Potential association with breast cancer risk

Genetic and epigenetic modifications of adiponectin gene: Potential association with breast cancer risk

Molecular Profiling of Breast Cancer Susceptibility of Obese or Insulin-Resistant and Pre-Diabetic Patients Using ITLN1 and CD295 SNPs

Characteristics of Special Type Breast Tumors in Our Center

Contact Info

Product

Resources

About